MI-ONESTREAM-SOFTWARE
29.3.2021 12:02:05 CEST | Business Wire | Press release
OneStream Software , a leading provider of modern corporate performance management (CPM) solutions for mid-sized to large enterprises, has been recognized as a market leader in the Business Application Research Center’s (BARC) global report on financial performance management software solutions. The BARC Score Financial Performance Management Global 2021 report places OneStream as a market leader with among the highest Portfolio Capabilities scores across vendors.
After hiring more than 270 employees throughout 2020, the company exceeded its 2020 projections and achieved 85 percent growth in Annual Recurring Revenue (ARR), accumulating more than 650 customers and achieving triple digit ARR CAGR in the EMEA region from 2017-2020. OneStream closed the year with 690 employees across 15 countries and more than 200 partners worldwide including PWC, Accenture and other general advisory firms. OneStream will continue to expand its workforce and partner ecosystem in 2021, including its opening of an Asia-Pacific (APAC) headquarters in Sydney, Australia.
“For OneStream to be recognized as a market leader in only the second year of coverage in the BARC Score report for Financial Performance Management solutions for global vendors reflects the broad capabilities of the platform and strong market adoption for global organizations worldwide. OneStream’s growth trajectory and commitment to 100% customer success positions the company to continue to challenge more established vendors as a leader in this market,” said Dr. Christian Fuchs, Senior Vice-President and Head of Data & Analytics Research at BARC.
The BARC Score report noted OneStream’s unified CPM platform for financial consolidation, close reporting and planning with built-in financial analytic engine and financial data quality capabilities as a strength, along with integrated analysis and reporting functionality. BARC also identified the OneStream MarketPlace, which hosts more than 50 downloadable business and productivity solutions optimized for the platform, as another strength. Overall, the report cited OneStream as having “excellent customer feedback for many important KPIs in BARC’s Planning Survey.”
“We are proud to be recognized in the BARC Score Financial Performance Management Global report as a market leader,” said Ricardo Rasche, Senior Vice President of International Sales for OneStream Software. “The BARC Score validates our underlying commitment to delivering 100% customer success for global organizations based in Germany, Austria, Switzerland and across the world. We are honored by this distinction as a market leader among much more established legacy vendors in EMEA.”
Last year in BARC’s The Planning Survey 20 , OneStream earned 38 top ranks and a 97% customer recommendation score. The BARC Score Financial Performance Management Global report examines global vendors, evaluating different criteria on two axes, “Portfolio Capabilities” and “Market Execution.” Vendors evaluated generated more than 20 million EUR in license revenue per year with its product set across EMEA, North America, Latin America and/or Asia-Pacific.
OneStream is helping a growing list of companies worldwide digitally transform finance and support strategic business decisions across the enterprise. OneStream customers are able to replace multiple legacy applications with OneStream’s unified Intelligent Finance platform and streamline key finance processes. Valued at more than $1B in 2019 and backed by global investment firm KKR, OneStream recently announced 2020 results and is well poised for a strong 2021.
To download the full report, click here .
About OneStream Software
OneStream Software provides a market-leading intelligent finance platform that reduces the complexity of financial operations. OneStream unleashes the power of finance by unifying corporate performance management (CPM) processes such as planning, financial close & consolidation, reporting and analytics through a single, extensible solution. We empower the enterprise with financial and operational insights to support faster and more informed decision-making. All in a cloud platform designed to continually evolve and scale with your organization.
OneStream is an independent software company backed by private equity investor KKR. With over 600 customers, 200 partners and over 700 employees our primary mission is to deliver 100% customer success. To learn more visit www.onestreamsoftware.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005071/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom